SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Basilea to Initiate Phase 2/3 Study in Mid-2027

Basilea Pharmaceutica plans to initiate a Phase 2/3 study for ceftibuten-ledaborbactam in mid-2027.

Related stories